Hi NMusers,
I am trying to develop a population model of a drug that was given at a
single dose using the PK data from two studies with different dosage. In
one study with the higher dose (n=26, four-way cross-over), it seems to
have three different patterns of kinetics: 1. the first measured
concentration is Cmax (fast absorption); 2. a secondary peak; 3. more
common oral PK with 1st-order Ka(normal absorption). In the other study
with lower dose (n=46, two-way cross-over), the overall kinetics are less
variable within the study. But there are about 30% subjects have about 50%
higher Cmax than others.
I tried one-compartment, two-compartment and ALAG models to fit the PK from
the first study with higher dose and also played with the introduction of
BOV and BSV on Ka and/or TLAG. All the models generally cannot capture the
absorption very well with an underprediction of Cmax. And None of the
complex models really gave improved fitting compared to simple
one-compartment model. I also tested transit model and it didn't improve
the fitting either.
Then, I focused on the PK with fast and normal absorption only and exclude
the PK with the secondary peak. I found that two-compartment model can give
good fitting for PK with fast absorption and normal
absorption,respectively. The estimated Ka for fast and normal absorption PK
are three times different, and then I tried mixture model on Ka to fit the
two PK dataset together. But it suffered boundary failure and the
percentage of the subpopulations can not be estimated.
For the second study with lower dose, I have similar problem. The majority
of Cmax is underpredicted, but I have good fitting of elimination phase in
both case.
It seems that I exhausted the possibilities that I can think of. Can anyone
give some comments or suggestions ?
Thanks a lot!
Best,
--
Xu, Claire
Ph.D Candidate
Division of Clinical Pharmacology, Wishard Hospital
Indiana University School of Medicine
1001 West 10th Street, Myers W7122
Indianapolis, IN 46202
T - 317/7558242
Question about modeling variable absorption kinetics
2 messages
2 people
Latest: Jul 20, 2012
Dear Claire,
You may want to look at Zhou's paper, it has a summary of the different type of
absorption models.
Best regards,
Jean
Reference:
Pharmacokinetic Strategies in Deciphering Atypical Drug Absorption Profiles.
Honghui Zhou, J Clin Pharmacol 2003;43:211-227
Quoted reply history
From: [email protected] [mailto:[email protected]] On
Behalf Of Xu, Claire
Sent: Friday, July 20, 2012 12:05 AM
To: [email protected]
Subject: [NMusers] Question about modeling variable absorption kinetics
Hi NMusers,
I am trying to develop a population model of a drug that was given at a single
dose using the PK data from two studies with different dosage. In one study
with the higher dose (n=26, four-way cross-over), it seems to have three
different patterns of kinetics: 1. the first measured concentration is Cmax
(fast absorption); 2. a secondary peak; 3. more common oral PK with 1st-order
Ka(normal absorption). In the other study with lower dose (n=46, two-way
cross-over), the overall kinetics are less variable within the study. But there
are about 30% subjects have about 50% higher Cmax than others.
I tried one-compartment, two-compartment and ALAG models to fit the PK from the
first study with higher dose and also played with the introduction of BOV and
BSV on Ka and/or TLAG. All the models generally cannot capture the absorption
very well with an underprediction of Cmax. And None of the complex models
really gave improved fitting compared to simple one-compartment model. I also
tested transit model and it didn't improve the fitting either.
Then, I focused on the PK with fast and normal absorption only and exclude the
PK with the secondary peak. I found that two-compartment model can give good
fitting for PK with fast absorption and normal absorption,respectively. The
estimated Ka for fast and normal absorption PK are three times different, and
then I tried mixture model on Ka to fit the two PK dataset together. But it
suffered boundary failure and the percentage of the subpopulations can not be
estimated.
For the second study with lower dose, I have similar problem. The majority of
Cmax is underpredicted, but I have good fitting of elimination phase in both
case.
It seems that I exhausted the possibilities that I can think of. Can anyone
give some comments or suggestions ?
Thanks a lot!
Best,
--
Xu, Claire
Ph.D Candidate
Division of Clinical Pharmacology, Wishard Hospital
Indiana University School of Medicine
1001 West 10th Street, Myers W7122
Indianapolis, IN 46202
T - 317/7558242<tel:317%2F7558242>
This electronic transmission may contain confidential and/or proprietary
information and is intended to be for the use of the individual or entity named
above. If you are not the intended recipient, be aware that any disclosure,
copying, distribution or use of the contents of this electronic transmission is
prohibited. If you have received this electronic transmission in error, please
destroy it and immediately notify us of the error. Thank you.